Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Mouse Models for Validating Preclinical Candidates for Huntington’s Disease

In: Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 7.
Affiliations
Free Books & Documents
Review

Mouse Models for Validating Preclinical Candidates for Huntington’s Disease

X. William Yang et al.
Free Books & Documents

Excerpt

Ever since its original description by George Huntington in 1872, Huntington’s disease (HD) has been known as one of the most devastating inherited neurodegenerative disorders afflicting the human brain. Currently in the United States, there are about 30,000 patients with HD and another 150,000 people who are at a genetic risk of developing the disease. HD is characterized by the clinical triad of late-onset motor disturbances (i.e., chorea and dystonia), psychiatric deficits (i.e., depression, irritability, and psychosis), and cognitive decline (Bates et al., 2002). The majority of HD patients experience onset of symptoms around the age of 40 (adult-onset HD), and the disease relentlessly progresses until the patient’s death, which usually occurs within 10–20 years after disease onset. A small subset of HD patients experience the onset of symptoms before age 20 (juvenile HD), and these patients exhibit slightly different clinical features in that they tend to have more dystonia than chorea, as well as a higher incidence of epilepsy. Although the onset of HD is currently defined by the onset of motor deficits, recent studies using more sensitive motor studies, as well as cognitive studies, indicate that clinical manifestations of HD may occur years to decades before the onset of motor symptoms, and such deficits may correspond to the early and progressive cortical and striatal atrophy seen in presymptomatic HD patients (Aylward et al., 2004; Rosas et al., 2005, 2006).

PubMed Disclaimer

References

    1. Andreassen O. A., Dedeoglu A., Ferrante R. J., Jenkins B. G., Ferrante K. L., Thomas M., Friedlich A., Browne S. E., Schilling G., Borchelt D. R., et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis. 2001;8(3):479–91. - PubMed
    1. Arguello P. A., Gogos J. A. Modeling madness in mice: one piece at a time. Neuron. 2006;52(1):179–96. - PubMed
    1. Aron A. R., Sahakian B. J., Robbins T. W. Distractibility during selection-for-action: differential deficits in Huntington’s disease and following frontal lobe damage. Neuropsychologia. 2003;41(9):1137–47. - PubMed
    1. Arrasate M., Mitra S., Schweitzer E. S., Segal M. R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805–10. - PubMed
    1. Aylward E. H., Sparks B. F., Field K. M., Yallapragada V., Shpritz B. D., Rosenblatt A., Brandt J., Gourley L. M., Liang K., Zhou H., et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004;63(1):66–72. - PubMed

LinkOut - more resources